Company profile
Celgene Corporation
Privately held: no public share price (Celgene Corporation was acquired by Bristol-Myers Squibb in a completed merger, November 2019 (~$74B); it now operates as a wholly owned BMS subsidiary and no longer files or trades independently. Sources: https://clinicaltrials.gov/study/NCT00044018 Entity resolved by asset-pipeline-v2.)
Assets
(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Cereblon E3 ubiquitin-ligase · Undisclosed / early pipelineSmall molecule | Multiple Myeloma | |
Sotatercept(Winrevair) | Approved | Activin receptor type IIA (ActRIIA)Protein / enzyme therapeutic | HypertensionHeart FailureNon-Small Cell Lung Cancer |
CC-223No recent activity | Phase 3 | mTOR (inhibitor)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.